TwinBeech Capital’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$610K Buy
+23,600
New +$665K 0.14% 204
2023
Q4
– Sell
-104,610
Closed -$1.88M – 867
2023
Q3
$1.88M Buy
+104,610
New +$2.1M 0.04% 419
2023
Q1
– Sell
-129,642
Closed -$2.68M – 842
2022
Q4
$2.68M Buy
+129,642
New +$3.57M 0.05% 374
2022
Q2
– Sell
-10,635
Closed -$336K – 692
2022
Q1
$336K Buy
+10,635
New +$356K 0.01% 421

Other funds holding RCUS

TwinBeech Capital's RCUS Position: Q3 2026 in Review

TwinBeech Capital opened a new position in Arcus Biosciences (RCUS) in Q3 2026: 23,600 shares worth $610K. The stake represents 0.14% of the portfolio and ranks #204 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in RCUS as recently as Q3 2023.

TwinBeech Capital first reported a position in RCUS in Q1 2022 and has held it in 4 quarters since. The position peaked at $2.68M in Q4 2022. 244 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

  • TwinBeech Capital held 23,600 shares of Arcus Biosciences worth $610K as of Q3 2026.
  • Arcus Biosciences was a new TwinBeech Capital position in Q3 2026.
  • Arcus Biosciences made up 0.14% of TwinBeech Capital's portfolio in Q3 2026, its #204 holding.
  • TwinBeech Capital first reported a position in Arcus Biosciences in Q1 2022 and has held it in 4 quarters since.
  • TwinBeech Capital's Arcus Biosciences position peaked at $2.68M in Q4 2022.
  • 244 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on TwinBeech Capital's 13F filing for Q3 2026, filed 16 Nov 2026.